UNSPSC 51433918: Tiadenol

This classification denotes a fatty alcohol and hypolipidemic agent with the molecular formula C14H30O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22251270CX, chemically known as 1,10-bis(hydroxyethylthio)decane but generally known as tiadenol, which bears US NIH Compound Identifier 23403. European Medicines Agency schedules Tiadenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10998MIG.

World Health Organization schedules tiadenol in its Anatomical Therapeutic Chemical (ATC) Classification. TIADENOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiadenol under HS 29309085 and SITC 51549. As of Q4 2014, TIADENOL remains the US FDA Preferred Term for this commodity. SMILES: S(CCCCCCCCCCSCCO)CCO.

UNSPSC 51433918 Tiadenol is a Commodity code covering advanced life support medications and pharmaceutical products supplied to state and local government agencies, particularly emergency medical services and public health systems. State and local governments procure under this code primarily injectable medications for emergency care, generic multi-source pharmaceuticals for health benefit programs, and over-the-counter products distributed through authorized public sector channels. The City of Tampa's Purchasing Department and the Texas Health and Human Services Commission exemplify the issuing-body mix: municipal fire rescue services, state health agencies, and multistate cooperative purchasing alliances all solicit under this code. Work solicited ranges from small, single-jurisdiction sealed-bid procurements for specific medication line items to large cooperative purchasing agreements serving multiple states and government employee populations.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications (Labetalol HCI, Epinephrine, Adenosine, and Diltiazem) due April 8, 2026, with an estimated contract value of $40,000.00 and a one-year term plus renewal and extension options; the procurement included a 5 percent Small Local Business Enterprise bid discount and required Safety Data Sheet compliance and WCAG 2.2 accessibility documentation. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capacity information on direct-to-manufacturer prescription programs serving self-insured employee health plans outside traditional pharmacy benefit manager channels, signaling upstream state interest in alternative pharmaceutical distribution models. The Minnesota Department of Administration's Office of State Procurement administered MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities in Minnesota and Oregon, due March 26, 2026, with contract effectiveness on July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain relationships with AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson Co. as authorized wholesalers and certify compliance with cGMP and Drug Supply Chain Security Act standards.